An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance (AMR) who will share their knowledge and opinions the current state of the AMR R&D field.
Register for Live Webinar Sept. 24, 2020 9:30-11:30AM
IBT Bioservices Transforms Identity, Elevates Focus on Contract Research Services
CARB-X global partnership headed toward developing an innovative vaccine against
IBT CEO Dr. M. Javad Aman will discuss the development
Subscribe to the IBT Bioservices Tech Talk list and receive periodic updates on industry news and IBT Bioservices products and services.
One of the most powerful applications of flow cytometry is for evaluating drug and vaccine efficacy. Multiparameter flow cytometry relies on the use of fluid systems, fluorescent proteins, and optical
The increasing rate of bacterial resistance creates a challenging environment for the development of therapies for bacterial infections. Bacterial skin infections are one of the leading manifestations of infectious diseases
